ALK-EML4 fusions have been reported in 2–7% of patients with advanced non-small-cell lung cancer (NSCLC) [20], and clinical trials are ongoing to determine if ALK inhibitors are currently approved for use in NSCLC can effectively target these fusions and overcome resistance. This evidence concerns the gene ALK and non-small cell lung carcinoma.